AU2002219071A1 - Compositions containing hydrolytically unstable compositions - Google Patents

Compositions containing hydrolytically unstable compositions

Info

Publication number
AU2002219071A1
AU2002219071A1 AU2002219071A AU1907102A AU2002219071A1 AU 2002219071 A1 AU2002219071 A1 AU 2002219071A1 AU 2002219071 A AU2002219071 A AU 2002219071A AU 1907102 A AU1907102 A AU 1907102A AU 2002219071 A1 AU2002219071 A1 AU 2002219071A1
Authority
AU
Australia
Prior art keywords
layer
pharmaceutical formulation
pharmaceutically active
coating
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219071A
Other languages
English (en)
Inventor
Debra Alida Odink
I-Lan Sue
Gary Conard Visor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002219071A1 publication Critical patent/AU2002219071A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
AU2002219071A 2000-11-10 2001-11-02 Compositions containing hydrolytically unstable compositions Abandoned AU2002219071A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24725700P 2000-11-10 2000-11-10
US60/247,257 2000-11-10
US32627401P 2001-10-01 2001-10-01
US60/326,274 2001-10-01
PCT/EP2001/012714 WO2002038133A2 (en) 2000-11-10 2001-11-02 Compositions containing hydrolytically unstable compounds

Publications (1)

Publication Number Publication Date
AU2002219071A1 true AU2002219071A1 (en) 2002-05-21

Family

ID=26938563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219071A Abandoned AU2002219071A1 (en) 2000-11-10 2001-11-02 Compositions containing hydrolytically unstable compositions

Country Status (12)

Country Link
US (1) US20020086057A1 (ko)
EP (1) EP1341529A2 (ko)
JP (1) JP2004520275A (ko)
KR (1) KR20030051794A (ko)
CN (1) CN1474686A (ko)
AR (1) AR037134A1 (ko)
AU (1) AU2002219071A1 (ko)
BR (1) BR0115206A (ko)
CA (1) CA2425594A1 (ko)
MX (1) MXPA03004040A (ko)
PE (1) PE20020586A1 (ko)
WO (1) WO2002038133A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20040313A1 (it) * 2004-02-24 2004-05-24 S I I T S R L Servizio Interna Formulazioni gastroprotette di inbitori di enzimi ad attivita' alfa-amilasica
US20060069079A1 (en) * 2004-09-27 2006-03-30 Sever Nancy E Stable amorphous cefdinir
WO2011013082A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
MX344189B (es) 2010-03-31 2016-12-08 Supernus Pharmaceuticals Inc Formulaciones de mazindol.
US11207271B2 (en) 2016-03-09 2021-12-28 Nls Pharmaceutics Ag Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
JPH08333238A (ja) * 1995-06-02 1996-12-17 Shin Etsu Chem Co Ltd 液体状ワックスを用いる無溶媒腸溶性コーティング剤で被覆した腸溶性製剤
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції

Also Published As

Publication number Publication date
WO2002038133A3 (en) 2003-01-23
CN1474686A (zh) 2004-02-11
MXPA03004040A (es) 2003-08-19
BR0115206A (pt) 2003-10-07
US20020086057A1 (en) 2002-07-04
WO2002038133A2 (en) 2002-05-16
CA2425594A1 (en) 2002-05-16
PE20020586A1 (es) 2002-07-06
EP1341529A2 (en) 2003-09-10
KR20030051794A (ko) 2003-06-25
JP2004520275A (ja) 2004-07-08
AR037134A1 (es) 2004-10-27

Similar Documents

Publication Publication Date Title
EP0502556B1 (en) Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds
KR100405586B1 (ko) 신규한제약제형및이의제조방법
SK284758B6 (sk) Perlička s regulovaným uvoľňovaním, spôsob jej výroby, viacjednotkový prípravok s jej obsahom a jej použitie
US20060051421A1 (en) Stable pharmaceutical formulations of benzimidazole compounds
KR20010093822A (ko) 신규한 제약 제형
WO1999061022A1 (en) A stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole
CA2488868A1 (en) Controlled release formulation of lamotrigine
WO2012001705A2 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2011140446A2 (en) Pharmaceutical formulations
CA2851327C (en) Coated pellets of omeprazole
JP2813809B2 (ja) 有核顆粒製剤およびその製造法
US20020086057A1 (en) Stabilized fromulations comprising hydrolytically unstable compositions
EP2345408A2 (en) Acid labile drug formulations
EP1594479A1 (en) Stable oral benzimidazole compositions and processes for their preparation
US20040170689A1 (en) Stabilized formulations comprising hydrolytically unstable compositions
ZA200302972B (en) Compositions containing hydrolytically unstable compounds.
JPH0873345A (ja) 医薬製剤
WO2005051362A2 (en) Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
WO2010018593A2 (en) Gastric acid resistant benzimidazole multiple unit tablet composition
US20120082718A1 (en) Morphine Formulations
AU695774C (en) New pharmaceutical formulation and process
MXPA00008985A (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
IL139894A (en) Stable benzimidazole composition and a method for producing it

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application